Key result
Novel oral anticoagulants offer advantages over warfarin for treating venous thromboembolism in older adults, including fewer drug interactions and lower bleeding risk, though caution is required.
Why the study?
What is the pathogenesis, diagnosis, and optimal treatment approach for venous thromboembolism in older adults?
Population
Older adults with or at risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism
Comparison
Antithrombotic agents, specifically novel oral… vs Warfarin
Design
Review
Authors
Loading...
Supports cautious NOAC preference in older VTE; leaves open dedicated RCTs for confirmation.
What is the pathogenesis, diagnosis, and optimal treatment approach for venous thromboembolism in older adults?
This review highlights that while VTE is common and often underrecognized in older adults, NOACs offer a promising alternative to warfarin with potentially lower bleeding risks, provided modifiable risk factors are managed.
Johnson et al. (2016) conducted a review in Venous Thromboembolism (VTE). Novel oral anticoagulants (NOACs) vs. Warfarin was evaluated. Novel oral anticoagulants offer advantages over warfarin for treating venous thromboembolism in older adults, including fewer drug interactions and lower bleeding risk, though caution is required.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: